Trial Outcomes & Findings for Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease (NCT NCT03619811)

NCT ID: NCT03619811

Last Updated: 2021-09-20

Results Overview

Response will be assessed binary as positive or negative where a positive response is defined by a post-treatment reflux symptom index (RSI) score ≤ 13 and a 33% change from comparator RSI. The minimum value is 0 and the maximum value is 45. The lower the score means less reported symptoms and the higher the score means more reported symptoms.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

43 participants

Primary outcome timeframe

Week 8 (Completion)

Results posted on

2021-09-20

Participant Flow

Participant milestones

Participant milestones
Measure
Symptomatic
This study examines the efficacy of the upper esophageal sphincter assist device as an adjunct to Proton-pump inhibitors (PPI) therapy in symptomatic subjects. (Reflux Band® Upper Esophageal Sphincter (UES) Assist Device) Reflux Band® Upper Esophageal Sphincter (UES) Assist Device: UES augmentation via the UES assist device is effective in true Reflux associated laryngeal symptoms. In our first pilot trial with the UES assist device, patients had significant symptom reduction following 2 weeks of UES assist device use. Based on our preliminary work, we theorize that the UES assist device is effective in Reflux associated laryngeal symptoms.
Overall Study
STARTED
43
Overall Study
COMPLETED
31
Overall Study
NOT COMPLETED
12

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Symptomatic
n=43 Participants
This study examines the efficacy of the upper esophageal sphincter assist device as an adjunct to Proton-pump inhibitors (PPI) therapy in symptomatic subjects. (Reflux Band® Upper Esophageal Sphincter (UES) Assist Device) Reflux Band® Upper Esophageal Sphincter (UES) Assist Device: UES augmentation via the UES assist device is effective in true Reflux associated laryngeal symptoms. In our first pilot trial with the UES assist device, patients had significant symptom reduction following 2 weeks of UES assist device use. Based on our preliminary work, we theorize that the UES assist device is effective in Reflux associated laryngeal symptoms.
Age, Categorical
<=18 years
0 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
33 Participants
n=99 Participants
Age, Categorical
>=65 years
10 Participants
n=99 Participants
Age, Continuous
50.48 years
STANDARD_DEVIATION 15.1 • n=99 Participants
Sex: Female, Male
Female
26 Participants
n=99 Participants
Sex: Female, Male
Male
17 Participants
n=99 Participants
Race/Ethnicity, Customized
White / Caucasian
26 Participants
n=99 Participants
Race/Ethnicity, Customized
Black
1 Participants
n=99 Participants
Race/Ethnicity, Customized
Asian
2 Participants
n=99 Participants
Race/Ethnicity, Customized
Hispanic
10 Participants
n=99 Participants
Race/Ethnicity, Customized
Other
4 Participants
n=99 Participants
Region of Enrollment
United States
43 participants
n=99 Participants
Reflux Symptom Index Baseline
24.1 units on a scale
STANDARD_DEVIATION 10.9 • n=99 Participants

PRIMARY outcome

Timeframe: Week 8 (Completion)

Population: This analysis includes the participants that completed phase 1 \& 2 of the study.

Response will be assessed binary as positive or negative where a positive response is defined by a post-treatment reflux symptom index (RSI) score ≤ 13 and a 33% change from comparator RSI. The minimum value is 0 and the maximum value is 45. The lower the score means less reported symptoms and the higher the score means more reported symptoms.

Outcome measures

Outcome measures
Measure
Symptomatic
n=31 Participants
This study examines the efficacy of the upper esophageal sphincter assist device as an adjunct to Proton-pump inhibitors (PPI) therapy in symptomatic subjects. (Reflux Band® Upper Esophageal Sphincter (UES) Assist Device) Reflux Band® Upper Esophageal Sphincter (UES) Assist Device: UES augmentation via the UES assist device is effective in true Reflux associated laryngeal symptoms. In our first pilot trial with the UES assist device, patients had significant symptom reduction following 2 weeks of UES assist device use. Based on our preliminary work, we theorize that the UES assist device is effective in Reflux associated laryngeal symptoms.
Patient-reported Symptom Response to Treatment Measured by the Reflux Symptom Index (RSI) Score
15.5 score on a scale
Standard Deviation 10.3

PRIMARY outcome

Timeframe: Week 4

Population: This population completed phase 1.

Response will be assessed binary as positive or negative where a positive response is defined by a post-treatment reflux symptom index (RSI) score ≤ 13 and a 33% change from comparator RSI. The minimum value is 0 and the maximum value is 45. The lower the score means less reported symptoms and the higher the score means more reported symptoms.

Outcome measures

Outcome measures
Measure
Symptomatic
n=36 Participants
This study examines the efficacy of the upper esophageal sphincter assist device as an adjunct to Proton-pump inhibitors (PPI) therapy in symptomatic subjects. (Reflux Band® Upper Esophageal Sphincter (UES) Assist Device) Reflux Band® Upper Esophageal Sphincter (UES) Assist Device: UES augmentation via the UES assist device is effective in true Reflux associated laryngeal symptoms. In our first pilot trial with the UES assist device, patients had significant symptom reduction following 2 weeks of UES assist device use. Based on our preliminary work, we theorize that the UES assist device is effective in Reflux associated laryngeal symptoms.
Patient-reported Symptom Response to Treatment Measured by the Reflux Symptom Index (RSI) Score
21.9 score on a scale
Standard Deviation 9.7

Adverse Events

Symptomatic

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Symptomatic
n=43 participants at risk
This study examines the efficacy of the upper esophageal sphincter assist device as an adjunct to Proton-pump inhibitors (PPI) therapy in symptomatic subjects. (Reflux Band® Upper Esophageal Sphincter (UES) Assist Device) Reflux Band® Upper Esophageal Sphincter (UES) Assist Device: UES augmentation via the UES assist device is effective in true Reflux associated laryngeal symptoms. In our first pilot trial with the UES assist device, patients had significant symptom reduction following 2 weeks of UES assist device use. Based on our preliminary work, we theorize that the UES assist device is effective in Reflux associated laryngeal symptoms.
Musculoskeletal and connective tissue disorders
Discomfort
2.3%
1/43 • Number of events 1 • 26 months
Standard definitions of adverse event and/or serious adverse event were used to collect adverse event information.

Additional Information

Clinical Research Coordinator

UCSD

Phone: 858-246-5236

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place